Patents Examined by Laura Daniel
  • Patent number: 9867806
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3, L, and the subscript m are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions, and methods of treatment using the same, for the treatment of cystic fibrosis by administering a compound of the invention.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: January 16, 2018
    Assignee: Galapagos NV
    Inventors: Ann De Blieck, Tom Roger Lisette De Munck, Caroline Martine Andrée Marie Joannesse, Hans Kelgtermans, Oscar Mammoliti, Christel Jeanne Marie Menet, Giovanni Alessandro Tricarico, Steven Emiel Van der Plas
  • Patent number: 9855265
    Abstract: The present disclosure relates to novel synthetic substituted heterocyclic compounds and pharmaceutical compositions containing the same, said compounds being capable of inhibiting or antagonizing TrkA receptor tyrosine kinases. In some aspects, the disclosure provides a compound having a structural formula (I): The disclosure further concerns the use of such compounds in the treatment and/or prevention of certain types of cancers, pain, inflammation, restenosis, atherosclerosis, psoriasis, thrombosis, Alzheimer's, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: January 2, 2018
    Assignee: VM Oncology, LLC.
    Inventor: Jay Jie-Qiang Wu
  • Patent number: 9840512
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: December 12, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Linda L. Brockunier, Helen Chen, Harry R. Chobanian, Matthew J. H. Clements, Alejandro Crespo, Duane E. DeMong, Yan Guo, William K. Hagmann, Karen M. Marcantonio, Michael Miller, Barbara Pio, Christopher W. Plummer, Dong Xiao
  • Patent number: 9840525
    Abstract: A crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) is provided. Also provided is a preparation method and method of using the crystal form. Specifically, a crystal form of 9-[(R)-2-[[(S)-[[[1-(isopropoxycarbonyl)-1-methyl]ethyl]amino]phenoxyphosphinyl]methoxyl]propyl]adenine fumarate of formula (I) having an X-ray powder diffraction (XRPD) spectrum including diffraction peaks at 2?±0.20° of 5.08, 12.44, 13.18, 22.37, 23.37 and 28.56 is provided. The crystal form provided herein has high bioavailability, significant efficacy, good stability, high yield and high purity, and contributes to the selection and design of a drug administration route and the determination of process parameters of a pharmaceutical preparation, thereby improving drug production quality.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: December 12, 2017
    Assignee: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Ming Chen, Chengyao Tian, Mingli Zhao, Jun Yu, Baohai Yang, Aifeng Lu
  • Patent number: 9834532
    Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: December 5, 2017
    Assignee: BOSTON BIOMEDICAL, INC.
    Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
  • Patent number: 9828360
    Abstract: Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(?X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: November 28, 2017
    Assignee: Array BioPharma Inc.
    Inventors: Shelley Allen, Steven Wade Andrews, James F. Blake, Barbara J. Brandhuber, Kevin Ronald Condroski, Julia Haas, Yutong Jiang, Timothy Kercher, Gabrielle R. Kolakowski, Shannon L. Winski
  • Patent number: 9828338
    Abstract: Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 28, 2017
    Assignees: The Regents of the University of California, Fondazione Istituto Italiano di Technologia, Universita Degli Studi di Urbino “Carlo Bo”, Universita Degli Studi di Parma
    Inventors: Daniele Piomelli, Tiziano Bandiera, Fabio Bertozzi, Andrea Nuzzi, Annalisa Fiasella, Stefano Ponzano, Chiara Pagliuca, Angelo Mario Reggiani, Marco Mor, Giorgio Tarzia
  • Patent number: 9822141
    Abstract: The present invention provides N-alkyl 2-(disubstituted)alkynyladenosine-5?-uronamides and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
    Type: Grant
    Filed: June 27, 2015
    Date of Patent: November 21, 2017
    Assignee: Lewis and Clark Pharmaceuticals, Inc.
    Inventors: Robert D Thompson, Anthony Beauglehole, Guoquan Wang
  • Patent number: 9822138
    Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: November 21, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Petr Vachal, Izzat Raheem, Zhiqiang Guo, Timothy John Hartingh
  • Patent number: 9822103
    Abstract: There are disclosed compounds that are inhibitors of EZH2, pharmaceutical compositions containing said compounds and methods of treating hyperproliferative, inflammatory, infectious, and immunoregulatory disorders and diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: November 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Steven P. Seitz, Jay A. Markwalder, Ashok Vinayak Purandare
  • Patent number: 9815799
    Abstract: Provided are a surface-modifying agent that enables production of a coating film that preserves transparency of a substrate while displaying high water repellency and excellent stain resistance, particularly in terms of wipeability of oil-based ink, and also an article for which the surface-modifying agent is used. The surface-modifying agent includes a triazine skeleton, a (meth)acrylate group bonded to the triazine skeleton via an urethane bond, and a perfluoropolyether chain bonded to the triazine skeleton.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: November 14, 2017
    Assignee: DEXERIALS CORPORATION
    Inventors: Makiya Ito, Kenji Kobayashi, Nobuo Tano, Kyungsung Yun
  • Patent number: 9802891
    Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 31, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hongyuan Wei, Chongjun Liu, Xuyang Zhao, Xiaojie Xu, Hua Bai, Yuncai Zhang
  • Patent number: 9802946
    Abstract: Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorder such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: October 31, 2017
    Assignee: Northwestern University
    Inventors: M. Amin Khan, Joseph R. Moskal, Paul Wood
  • Patent number: 9801845
    Abstract: Antimicrobial compositions comprising sulfur- or selenium-containing, fatty-acylated alpha-hydroxy acid compounds and methods of using said compounds or compositions to inhibit microbial growth.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 31, 2017
    Assignee: Novus International, Inc.
    Inventors: Graciela B. Arhancet, Matthew Mahoney, Scott Long, Mariya Grega, Drew L. Lichtenstein, Vivek Kuttappan, Jeffery Escobar Monestel, Mercedes Vazquez-Anon
  • Patent number: 9801951
    Abstract: In certain aspects, compounds and uses thereof are provided. In certain aspects, compound-conjugates and uses thereof are provided.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 31, 2017
    Assignee: Concortis Biosystems, Corp.
    Inventors: Zhenwei Miao, Yufeng Hong, Tong Zhu
  • Patent number: 9796714
    Abstract: Embodiments of calcium channel agonists, as well as methods of making and using the calcium channel agonists, are disclosed. The disclosed calcium channel agonists and corresponding salt forms have a structure according to general formula I: wherein each bond depicted as “” is a single bond or a double bond as needed to satisfy valence requirements; Z1, Z2, Z3, Z4, and Z5 independently are nitrogen or carbon; R1 and R3 are alkyl; R2 is alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and R4 is alkyl or hydroxyalkyl.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: October 24, 2017
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Peter Wipf, Stephen D. Meriney, Mary Liang
  • Patent number: 9796688
    Abstract: Provided is a method for the synthesis of N-protected bis-3,6-[4-aminobutyl]-2,5-diketopiperazine including the step of heating a solution of ?-amino protected lysine in the presence of a catalyst selected from the group consisting of sulfuric acid, phosphoric acid, and phosphorus pentoxide.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: October 24, 2017
    Assignee: MannKind Corporation
    Inventors: John J. Stevenson, Destardi Moye-Sherman
  • Patent number: 9782390
    Abstract: The present invention relates to novel ?-lactam compounds, their preparation and use. In particular, this invention relates to novel ?-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: October 10, 2017
    Assignee: AiCuris GmbH & Co. KG
    Inventors: Burkhard Klenke, Irith Wiegand, Guido Schiffer, Heike Broetz-Oesterhelt, Samarendra N. Maiti, Jehangir Khan, Andhe Reddy, Zhixiang Yang, Mostafa Hena, Guofeng Jia, Ou Ligong, Hong Liang, Judy Yip, Chuanjun Gao, Sabiha Tajammul, Rahim Mohammad, Ganguli Biswajeet
  • Patent number: 9777028
    Abstract: The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: October 3, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Bing Shi, Zhuoyi Su, Fang Wang
  • Patent number: 9776959
    Abstract: The present invention provides crystal forms of the compound of (3R,4S)-4-(4-hydroxyphenyl)-3-[3-(4-fluorophenyl)-4-hydroxybut-2(Z)-enyl]-1-(4-fluorophenyl)-2-azetidinone (formula A). The crystal forms can be characterized by X-ray powder diffraction (XRPD) spectra, differential scanning calorimetry (DSC) spectra, infrared absorption spectra and so on. Meanwhile, the present invention also provides methods for preparing the crystal forms of the compound of formula A, pharmaceutical compositions and uses thereof.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 3, 2017
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hongyuan Wei, Chongjun Liu, Xuyang Zhao, Xiaojie Xu, Hua Bai, Yuncai Zhang